Navigation Links
Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
Date:9/6/2007

Close to 1 million Medicare patients develop pressure ulcers costing the

system more than $10 billion annually

BATESVILLE, Ind., Sept. 6 /PRNewswire-FirstCall/ -- Today, findings of the 10th Annual International Pressure Ulcer Prevalence Survey (IPUPS) were released by Hill-Rom, the health care unit of Hillenbrand Industries (NYSE: HB) and a leading provider of medical technology for hospitals and other care sites around the world. These results document the potential for decreasing by half the incidence rate of pressure ulcers in acute care facilities and substantiate an opportunity for hospitals to dramatically reduce hospital-acquired pressure ulcers through specially designed prevention programs. The study is of particular interest following the Centers for Medicare and Medicaid Services (CMS) recent announcement that treatment of hospital-acquired pressure ulcers would no longer be reimbursed.

The broad and in-depth survey documented that nearly half of all adult patients in acute care facilities were assessed to be at high risk for the development of pressure ulcers. Although hospitals are beginning to incorporate comprehensive pressure ulcer prevention programs, still over 75 percent of the high risk patients did not receive such a program. Implementing a comprehensive approach like the new Safe Skin(TM) Program offered by Hill-Rom was shown in the IPUPS data to significantly decrease the incidence rate of pressure ulcers from 7.8 percent to 3.8 percent in the high risk group.

Based on the survey prevalence, it can be estimated that over 900,000 Medicare patients annually will develop pressure ulcers. According to a 2003 study reported in the Journal of the American Medical Association (JAMA), the excess cost of treating a hospital-acquired pressure ulcer is $10,845, potentially leading to more than $10 billion of total Medicare reimbursements annually. The recent CMS announcement regarding pressure ulcer treatment
'/>"/>

SOURCE Hillenbrand Industries, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Apollo Hospitals to consider listing on US Bourses in 2003
2. Greater volume hospitals better for stroke
3. Apollo Hospitals Collaborates With Histostem For Stem Cell Therapy
4. Indian Hospitals – A Destination For Quality Medical Care
5. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
6. Indian hospitals require International Accreditation
7. Quality Awareness In Hospitals Can Reduce Mortality Rate Of Patients
8. First PET-CT guided radiotherapy in India was performed by Apollo Hospitals
9. Delhi Government To Interlink All Major Hospitals Through e-Governance
10. Global Hospitals coming to city of Joy
11. Religious Leaders condemn determination of sex in hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)... report side effects, but critics want agency to a...ealthDay News) -- Direct-to-consumer drug ads on t...that would allow consumers to report adverse side ..., The experts serve on a panel that advises the U....s are already mandated by the FDA for print ads. A...
(Date:5/16/2008)...eing presented at the American Society of Clinical... change treatment practice in about 25 percent of ...oposed changes to the way colorectal cancers will ...ncer Institute (NCI) SEER population-based statist...nical trial data, shows that outcomes of patients ...
(Date:5/16/2008)...s located just beneath the lining of the uterus (s...ial cavity after uterine artery embolization (UAE)...ding to a new study. , The study included 49 pa...ination before and after UAE. The study found that...ed to the endometrial cavity after UAE, said Sachi...
(Date:5/16/2008)... Cast Scheduled for May 19 at 10:15 a.m. Eastern T...esponse Biomedical,Corporation (TSX: RBM, OTCBB: R...cutive Officer, is scheduled to present at the Rod...nce on Monday May 19th at 10:15 a.m.,EDT., A live... the Company,s,Web site at, http://www.responsebio...
Breaking Medicine News(10 mins):Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
...f St Annes, Lancs, a mobile phone two years ago sh...constantly // sending text messages to her friends...s ‘repetitive strain injury’ and becoming the you...m this condition. Her mother, Jane, explains that...
...ntegrated Disease Surveillance Project to bring 11...out the country. // Union Health minister Ambuman...d Bank-funded project would be able to create a ve...ke HIV/AIDS, polio, cholera, cardio-vascular disea...
...ustralians are paying more on medicines than US li...al Medicines Symposium at Canberra, WHO’s Richard ... over the world for buying and valuing innovative ...hat triggers the Government to reduce the pay of g...
...ate and federal, experts warn that many million do... be squandered // . A psychiatrist, Ian Hickie sa...both were having clash in setting policies. The f...ofessor Hickie and Allan Fels said: due to lack of...
Other Medicine News:
(Date:5/16/2008)... RARITAN, N.J., May 16 /- Veridex, L..., Laboratory Corporation of America Holdings,(LabC...tion test for,prostate cancer. The new assay uses ... prostate cancer, detecting the methylation of the... that occurs primarily in,cancer. Veridex is devel...
(Date:5/15/2008)... BASEL, Switzerland, May 15 /- Patie...orld,s most common cancers, can expect,further tre...Herceptin(R),(trastuzumab) following new data that...f Clinical Oncology (ASCO) annual meeting in Chica...s will attend the meeting which,is the premier eve...
(Date:5/15/2008)... MELBOURNE, Australia, May 15 /PRNewswire-FirstCa...that the abstract for its upcoming oral,presentati...rican Society,of Clinical Oncology (ASCO) will be ...://www.asco.org ) from 9pm on Thursday 15 May (US ...valuation of CYT997, a novel,cytotoxic and vascula...
(Date:5/15/2008)... Excellent results obtained with a newly cleared d...y plaques of interest that are associated with ... BURLINGTON, Mass., May 15 /- InfraR...ont Hospital in Royal Oak, Mich., have,successfull... a patient,undergoing a cardiac catheterization. T...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4People not always needed to alleviate loneliness 1961 1People not always needed to alleviate loneliness 1961 2People not always needed to alleviate loneliness 1961 3Gene Networks in Animal Development and Evolution Feb 15 and 16 1959 1European Summit on Cardiovascular Disease Prevention 9763 1European Summit on Cardiovascular Disease Prevention 9763 2Stem cell research aims to tackle Parkinsons disease 1952 1Stem cell research aims to tackle Parkinsons disease 1952 2
...NSTEPHAN, Germany, March 29, 2007 /PRNewswire/ --,... therapeutic,products comprising of Anticalins(R),...ns, announced today it has demonstrated potent,ant...with PRS-050,a VEGF-specific Anticalin(R) with ex...enograft model, thereby supporting the,development...
...monstrates 50% Survival in Valortim-Treated,Animal...2007 - Medarex,Inc. (Nasdaq: MEDX), a leading mon... privately held biotechnology company dedicated,to...day announced,that Valortim, a fully human monoclo... the prevention and treatment of anthrax,infection...
Other Medicine Technology:Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific,Anticalin in Preclinical Studies 2Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific,Anticalin in Preclinical Studies 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7
This equipment is a fundus camera which is capable of mydriatic and non-mydriatic photography with two angles of,view: 50 and 25 (45 and 22 for non-mydriatic photography). You can record photograph
...is the worlds first tri-modal cataract removal sur...s surgeons to,choose from three different method... features revolutionary Fluidics and unique tri-mo... Liquefaction Device, Ultrasound and NeoSoniX hand...
...tware is a full-featured product capable of managi...lmic practice. This fully integrated solution offe...linical management needs of the eye care professio... can be implemented stand-alone or in an enterpris...
...uterized medical record system whose goal is to in...tice as well as improve the degree and ease of doc...monly presenting problems based on the chief compl...over rare diagnostic entities. It covers the chief...
Medicine Products: